The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3)
Open accessAbstract
The recurring translocation t(11;16)(q23;p13.3) has been documented only in cases of acute leukemia or myelodysplasia secondary to therapy with drugs targeting DNA topoisomerase II. We show that the MLL gene is fused to the gene that codes for CBP (CREB-binding protein), the protein that binds specifically to the DNA-binding protein CREB (cAMP response element-binding protein) in this translocation. MLL is fused in-frame to a different exon of CBP in two patients producing chimeric proteins containing the AT-hooks, methyltransferase homology domain, and transcriptional repression domain of MLL fused to the CREB binding domain or to the bromodomain of CBP. Both fusion products retain the histone acetyltransferase domain of CBP and may lead to leukemia by promoting histone acetylation of genomic regions targeted by the MLL AT-hooks, leading to transcriptional deregulation via aberrant chromatin organization. CBP is the first partner gene of MLL containing well defined structural and functional motifs that provide unique insights into the potential mechanisms by which these translocations contribute to leukemogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
Phosphorylated CREB binds specifically to the nuclear protein CBP
Chrivia, J. C., Kwok, R. P. S., Lamb, N., Hagiwara, M., Montminy, M. R., & Goodman, R. H. (1993) · Nature · doi:10.1038/365855a0 · Cited by 2,052
The CBP co-activator is a histone acetyltransferase
Bannister, A. J., & Kouzarides, T. (1996) · Nature · doi:10.1038/384641a0 · Cited by 1,805
Brownell, J. E., Zhou, J., Ranalli, T., Kobayashi, R., Edmondson, D. G., Roth, S. Y., & Allis, C. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81063-6 · Cited by 1,640
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479
Nuclear protein CBP is a coactivator for the transcription factor CREB
Kwok, R. P. S., Lundblad, J. R., Chrivia, J. C., Richards, J. P., Bächinger, H. P., Brennan, R. G., Roberts, S. G. E., Green, M. R., & Goodman, R. H. (1994) · Nature · doi:10.1038/370223a0 · Cited by 1,443
Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP
Petrif, F., Giles, R. H., Dauwerse, H. G., Saris, J. J., Hennekam, R. C. M., Masuno, M., Tommerup, N., van Ommen, G.-J. B., Goodman, R. H., Peters, D. J. M., et al. (1995) · Nature · doi:10.1038/376348a0 · Cited by 1,217
Tamkun, J. W., Deuring, R., Scott, M. P., Kissinger, M., Pattatucci, A. M., Kaufman, T. C., & Kennison, J. A. (1992) · Cell · doi:10.1016/0092-8674(92)90191-e · Cited by 971
Tkachuk, D. C., Kohler, S., & Cleary, M. L. (1992) · Cell · doi:10.1016/0092-8674(92)90602-9 · Cited by 920
Altered Hox expression and segmental identity in Mll-mutant mice
Yu, B. D., Hess, J. L., Horning, S. E., Brown, G. A. J., & Korsmeyer, S. J. (1995) · Nature · doi:10.1038/378505a0 · Cited by 875
Cited by
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
“3), a large portion of CBP, containing all but the most amino-terminal sequences, is fused onto the 3 end of the gene encoding MLL (Rowley et al. 1997; Sobulo et al. 1997).”
BackgroundTruncating mutations of hSNF5/INI1 in aggressive paediatric cancer
Versteege, I., Sévenet, N., Lange, J., Rousseau-Merck, M.-F., Ambros, P., Handgretinger, R., Aurias, A., & Delattre, O. (1998) · Nature · doi:10.1038/28212 · Cited by 1,556
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
p300/CBP proteins: HATs for transcriptional bridges and scaffolds
Chan, H. M., & La Thangue, N. B. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.13.2363 · Cited by 1,092
Yao, T.-P., Oh, S. P., Fuchs, M., Zhou, N.-D., Ch'ng, L.-E., Newsome, D., Bronson, R. T., Li, E., Livingston, D. M., & Eckner, R. (1998) · Cell · doi:10.1016/s0092-8674(00)81165-4 · Cited by 1,014
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L. H., Lerach, S., Tang, H., Ma, J., et al. (2011) · Nature · doi:10.1038/nature09730 · Cited by 949
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
BET domain co-regulators in obesity, inflammation and cancer
Belkina, A. C., & Denis, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3256 · Cited by 711
Iyer, N. G., Özdag, H., & Caldas, C. (2004) · Oncogene · doi:10.1038/sj.onc.1207118 · Cited by 638
Protein Lysine Acetylation by p300/CBP
Dancy, B. M., & Cole, P. A. (2015) · Chemical Reviews · doi:10.1021/cr500452k · Cited by 609
Histone acetylases and deacetylases in cell proliferation
Kouzarides, T. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80006-9 · Cited by 601
The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases
Yang, X.-J. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh252 · Cited by 515
Warrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1621 · Cited by 502
Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins
Ayton, P. M., & Cleary, M. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204639 · Cited by 500
CBP and p300: HATs for different occasions
Kalkhoven, E. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.03.045 · Cited by 496
Lund, A. H., & van Lohuizen, M. (2004) · Genes & Development · doi:10.1101/gad.1232504 · Cited by 489
Bromodomains as therapeutic targets
Muller, S., Filippakopoulos, P., & Knapp, S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001992 · Cited by 442
Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP
Kung, A. L., Rebel, V. I., Bronson, R. T., Ch'ng, L.-E., Sieff, C. A., Livingston, D. M., & Yao, T.-P. (2000) · Genes & Development · doi:10.1101/gad.14.3.272 · Cited by 440
Secondary leukemias induced by topoisomerase-targeted drugs
Felix, C. A. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00139-0 · Cited by 418
Li, B., Samanta, A., Song, X., Iacono, K. T., Bembas, K., Tao, R., Basu, S., Riley, J. L., Hancock, W. W., Shen, Y., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700298104 · Cited by 410
Conjunction dysfunction: CBP/p300 in human disease
Giles, R. H., Peters, D. J. M., & Breuning, M. H. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01438-3 · Cited by 403
THE CRITICAL ROLE OF CHROMOSOME TRANSLOCATIONS IN HUMAN LEUKEMIAS
Rowley, J. D. (1998) · Annual Review of Genetics · doi:10.1146/annurev.genet.32.1.495 · Cited by 397
Self-citationLinking the epigenetic ‘language’ of covalent histone modifications to cancer
Hake, S. B., Xiao, A., & Allis, C. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601575 · Cited by 385
Citterio, E., Van Den Boom, V., Schnitzler, G., Kanaar, R., Bonte, E., Kingston, R. E., Hoeijmakers, J. H. J., & Vermeulen, W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.20.7643-7653.2000 · Cited by 371
Karve, T. M., & Cheema, A. K. (2011) · Journal of Amino Acids · doi:10.4061/2011/207691 · Cited by 364
Chromatin modifier enzymes, the histone code and cancer
Santos-Rosa, H., & Caldas, C. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.010 · Cited by 337
p53 Acetylation: Regulation and Consequences
Reed, S., & Quelle, D. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 332
Estrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance
Ali, S., & Coombes, R. C. (2000) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009594727358 · Cited by 329
The molecular biology of mixed lineage leukemia
Slany, R. K. (2009) · Haematologica · doi:10.3324/haematol.2008.002436 · Cited by 321
Structural Mechanism of the Bromodomain of the Coactivator CBP in p53 Transcriptional Activation
Mujtaba, S., He, Y., Zeng, L., Yan, S., Plotnikova, O., Sachchidanand, Sanchez, R., Zeleznik-Le, N. J., Ronai, Z., & Zhou, M.-M. (2004) · Molecular Cell · doi:10.1016/s1097-2765(03)00528-8 · Cited by 319
Self-citationLeukaemogenesis: more than mutant genes
Chen, J., Odenike, O., & Rowley, J. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2765 · Cited by 311
Self-citationWang, F., Marshall, C. B., & Ikura, M. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1254-4 · Cited by 309
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Kitabayashi, I. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.2994 · Cited by 306
p300 and CBP: Partners for life and death
Giordano, A., & Avantaggiati, M. L. (1999) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199911)181:2<218::aid-jcp4>3.0.co;2-5 · Cited by 291
Mechanisms of therapy-related carcinogenesis
Allan, J. M., & Travis, L. B. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1749 · Cited by 277
CREB-binding protein and p300: molecular integrators of hematopoietic transcription
Blobel, G. A. (2000) · Blood · doi:10.1182/blood.v95.3.745.003k05_745_755 · Cited by 260
MLL and CREB Bind Cooperatively to the Nuclear Coactivator CREB-Binding Protein
Ernst, P., Wang, J., Huang, M., Goodman, R. H., & Korsmeyer, S. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.7.2249-2258.2001 · Cited by 252
Rosmarin, A. G., Yang, Z., & Resendes, K. K. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.08.015 · Cited by 121
Gervasini, C., Castronovo, P., Bentivegna, A., Mottadelli, F., Faravelli, F., Giovannucci-Uzielli, M. L., Pessagno, A., Lucci-Cordisco, E., Pinto, A. M., Salviati, L., et al. (2007) · Genomics · doi:10.1016/j.ygeno.2007.07.012 · Cited by 47
Metadata
- Authors
- Sobulo, O. M., Borrow, J., Tomek, R., Reshmi, S., Harden, A., Schlegelberger, B., Housman, D., Doggett, N. A., Rowley, J. D., & Zeleznik-Le, N. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-08-05
- Volume
- 94
- Issue
- 16
- Pages
- 8732-8737
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2166907165
- Cited by
- 319
- References
- 45
- FWCI
- 15.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.